Skip to Content

Company Aims to Cure Blindness with Optogenetics

The technique would retrain cells that typically don’t respond to light.

One biotech startup wants to restore vision in blind patients with a gene therapy that gives light sensitivity to neurons that don’t normally possess it.

The attempt, by Ann Arbor, Michigan-based Retrosense Therapeutics, will use so-called optogenetics. Scientists have used the technique over the last few years as a research tool to study brain circuits and the neural control of behavior by directing neuron activity with flashes of light. But Retrosense and others groups are pushing to bring the technique to patients in clinical trials.

The idea behind Retrosense’s experimental therapy is to use optogenetics to treat patients who have lost their vision due to retinal degenerative diseases such as retinitis pigmentosa. Patients with retinitis pigmentosa experience progressive and irreversible vision loss because the rods and cones of their eyes die due to an inherited condition. If the company is successful, the treatment could also help patients with the most common form of macular degeneration, which affects nearly a million people in the United States. The U.S. Food and Drug Administration hasn’t approved any therapies for either condition.

Retrosense is developing a treatment in which other cells in the retina could take the place of the rods and cones, cells which convert light into electrical signals. The company is targeting a group of neurons in the eye called ganglion cells. Normally, ganglion cells don’t respond to light. Instead, they act as a conduit for electrical information sent from the retina’s rods and cones. The ganglion cells then transmit visual information directly to the brain.

Doctors would inject a non-disease causing virus into a patient’s eye. The virus would carry the genetic information needed to produce the light-sensitive channel proteins in the ganglion cells. Normally, rods, cones, and other cells translate light information into a code of neuron-firing patterns that is then transmitted via the ganglion cells into the brain. Since Retrosense’s therapy would bypass that information processing, it may require the brain to learn how to interpret the signals. 

So far, Retrosense and its academic collaborators have shown that the treatment can restore some vision-evoked behaviors in rodents. The treatment also seems safe in nonhuman primates. The optogenetically modified ganglion cells of these primates are light-responsive, but behavioral tests aren’t possible, as there are no nonhuman primate models of retinal degeneration, says Retrosense CEO Sean Ainsworth.

Retrosense plans to begin its first clinical trial in 2013 with nine blind retinitis pigmentosa patients.

Keep Reading

Most Popular

Conceptual illustration of a therapy session
Conceptual illustration of a therapy session

The therapists using AI to make therapy better

Researchers are learning more about how therapy works by examining the language therapists use with clients. It could lead to more people getting better, and staying better.

street in Kabul at night
street in Kabul at night

Can Afghanistan’s underground “sneakernet” survive the Taliban?

A once-thriving network of merchants selling digital content to people without internet connections is struggling under Taliban rule.

Conceptual illustration showing a file folder with the China flag and various papers flying out of it
Conceptual illustration showing a file folder with the China flag and various papers flying out of it

The US crackdown on Chinese economic espionage is a mess. We have the data to show it.

The US government’s China Initiative sought to protect national security. In the most comprehensive analysis of cases to date, MIT Technology Review reveals how far it has strayed from its goals.

IBM engineers at Ames Research Center
IBM engineers at Ames Research Center

Where computing might go next

The future of computing depends in part on how we reckon with its past.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.